The RAS oncogene is both the most frequently mutated oncogene in human cancer and the
first confirmed human oncogene to be discovered in 1982. After decades of research, in …

After decades of efforts, we have recently made progress into targeting KRAS mutations in
several malignancies. Known as the 'holy grail'of targeted cancer therapies, KRAS is the …

Simple Summary The abundance and the dynamic of the studies on NSCLC require
frequent summaries of the current achievements in the field. In our review, we aimed to …

Extracellular vesicles (EVs) are nano-sized, membranous structures secreted into the
extracellular space. They exhibit diverse sizes, contents, and surface markers and are …

RAS is the most frequently mutated oncogene in human cancers, with mutations in about
30% of all cancers. RAS exists in three different isoforms (K-RAS, H-RAS and N-RAS) with …

Non-small-cell lung cancers (NSCLCs), the most common lung cancers, are known to have
diverse pathological features. During the past decade, in-depth analyses of lung cancer …

Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung
cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of …

In recent years, there has been a major paradigm shift in the management of non-small cell
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …

To characterize patient-derived xenografts (PDXs) for functional studies, we made whole-
genome comparisons with originating breast cancers representative of the major intrinsic …

Purpose: The molecular epidemiology of most EGFR and KRAS mutations in lung cancer
remains unclear. Experimental Design: We genotyped 3,026 lung adenocarcinomas for the …